The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / ACR/ARHP Annual Meeting 2012: New Insights into Bone Erosion and Formation Heighten Prospects for Therapies

ACR/ARHP Annual Meeting 2012: New Insights into Bone Erosion and Formation Heighten Prospects for Therapies

April 1, 2013 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Bone Out of Balance
With forces vying for bone destruction and for bone creation, the healthy outcome is a draw between the two—but that often doesn’t happen in those with arthritic conditions.


WASHINGTON, D.C.—New and potentially vital insights into the factors that lead to bone erosion and formation could point the way to new treatments for the terrible effects that arthritic conditions can have on bone, an expert on the subject said during the Rheumatology Research Foundation’s Oscar S. Gluck, MD, Memorial Lectureship, “Bone Wasn’t Built in a Day,” at the 2012 ACR/ARHP Annual Meeting, held November 9–14.

You Might Also Like
  • New Research Focuses on Bone Erosion and Repair in Rheumatoid Arthritis
  • ACR/ARHP Annual Meeting 2012: Risk of Immunosuppression from Rheumatic Disease Therapies Poses Challenge for Rheumatologists
  • 2014 ACR/ARHP Annual Meeting: Rheumatologic Research Uncovers Clues to Therapies
Explore This Issue
April 2013
Also By This Author
  • The ACR’s State-of-the-Art Clinical Symposium: Patients with Scleroderma, Lung Disease May Benefit from Aggressive Therapy

With forces vying for bone destruction and for bone creation, the healthy outcome is a draw between the two—but that often doesn’t happen in those with arthritic conditions, said Ellen Gravallese, MD, professor of medicine and cell biology at the University of Massachusetts Medical School in Boston.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The result is bone loss in rheumatoid arthritis (RA) and debilitating bone formation in conditions like ankylosing spondylitis. “Ultimately, there’s a balance between osteoclast-mediated bone resorption and osteoblast mediated bone formation,” Dr. Gravallese said. “And the question is, How is this balance maintained?”

Figuring out this process—and how it’s undermined in those with arthritic diseases—is a problem being tackled in laboratories throughout the world.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Reviewing Some Findings

Studies have found that bone edema is a sign of future bone erosion—one study of 55 patients found that synovitis and bone edema are independent predictors of erosion. “Areas of bone edema will likely result in an erosion if the patient is not treated,” Dr. Gravallese said. “However, early therapy can prevent progression to erosion.”1

In a finding now well known, the inhibition of RANK ligand has been identified as a way of keeping osteoclast precursor cells from differentiating into the cells that destroy bone.2

“This is one mechanism by which osteoclasts could be inhibited—that is, by inhibiting their differentiation,” Dr. Gravallese said. “And it’s been shown that the RANKL antibody has a profound effect on bone turnover.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

One area that has been a puzzle, she said, is why lupus patients seem to be more protected from erosion than RA patients, but there have been inroads into understanding this as well. A study out of the University of Rochester examined the role of interferon-alpha in a lupus mouse model as this process unfolds, yielding results that could have a bearing on clinical practice.

“Over time, as the mouse developed the lupus phenoytpe, interferon-alpha was increasingly produced—and during the phases of interferon-alpha production, erosion was not seen, even with arthritis, due to interferon-alpha expression,” Dr. Gravallese said. “This research showed that what interferon-alpha does in this model is to divert the precursor cells to a myeloid dendritic cell at the expense of osteoclast precursors. This might be one important mechanism by which lupus patients are protected from erosion.”

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, Osteoarthritis Tagged With: ACR/ARHP Annual Meeting, bone formation, bone loss, ResearchIssue: April 2013

You Might Also Like:
  • New Research Focuses on Bone Erosion and Repair in Rheumatoid Arthritis
  • ACR/ARHP Annual Meeting 2012: Risk of Immunosuppression from Rheumatic Disease Therapies Poses Challenge for Rheumatologists
  • 2014 ACR/ARHP Annual Meeting: Rheumatologic Research Uncovers Clues to Therapies
  • ACR/ARHP Annual Meeting 2012: Serum Antibodies Offer Useful Clinical Insights into Systemic Sclerosis

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)